These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 35280442)

  • 21. Longer time to radical cystectomy in patients treated with neoadjuvant chemotherapy is associated with worse oncological outcomes.
    Nuijens ST; van Osch FHM; van Hoogstraten LMC; Witjes JA; Aben KKH; Hermans TJN
    Urol Oncol; 2024 Apr; 42(4):117.e11-117.e16. PubMed ID: 38238116
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A delay ≥8 weeks to neoadjuvant chemotherapy before radical cystectomy increases the risk of upstaging.
    Audenet F; Sfakianos JP; Waingankar N; Ruel NH; Galsky MD; Yuh BE; Gin GE
    Urol Oncol; 2019 Feb; 37(2):116-122. PubMed ID: 30509868
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical Upstaging After Neoadjuvant Chemotherapy Impacting Eligibility for Vaginal-sparing Cystectomy: Identifying Bladder Cancer Patients Who May Benefit From Interim Imaging.
    Liu WJ; Campbell RA; Michael PD; Wood A; Haywood SC; Eltemamy M; Kaouk J; Campbell SC; Haber GP; Weight CJ; Remer EM; Almassi N
    Urology; 2024 Sep; 191():102-109. PubMed ID: 38908561
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Residual CIS after neoadjuvant chemotherapy and radical cystectomy for muscle invasive bladder cancer: Implications for neoadjuvant trials.
    Gabrielson AT; Daniels MJ; Rowe J; Alam R; Lee EJ; Matoso A; De Felice A; Hahn N; Hoffman-Censits J; Bivalacqua TJ; Kates M
    Urol Oncol; 2022 Apr; 40(4):164.e9-164.e16. PubMed ID: 35045949
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Delaying Radical Cystectomy After Neoadjuvant Chemotherapy for Muscle-invasive Bladder Cancer is Associated with Adverse Survival Outcomes.
    Boeri L; Soligo M; Frank I; Boorjian SA; Thompson RH; Tollefson M; Quevedo FJ; Cheville JC; Karnes RJ
    Eur Urol Oncol; 2019 Jul; 2(4):390-396. PubMed ID: 31277775
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Contemporary Rates of Gynecologic Organ Involvement in Females with Muscle Invasive Bladder Cancer: A Retrospective Review of Women Undergoing Radical Cystectomy following Neoadjuvant Chemotherapy.
    Bree KK; Hensley PJ; Westerman ME; Kokorovic A; Nogueras-Gonzalez GM; Dinney CP; Kamat AM; Navai N
    J Urol; 2021 Sep; 206(3):577-585. PubMed ID: 33872050
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cigarette smoking is associated with adverse pathological response and increased disease recurrence amongst patients with muscle-invasive bladder cancer treated with cisplatin-based neoadjuvant chemotherapy and radical cystectomy: a single-centre experience.
    Boeri L; Soligo M; Frank I; Boorjian SA; Thompson RH; Tollefson M; Quevedo FJ; Cheville JC; Karnes RJ
    BJU Int; 2019 Jun; 123(6):1011-1019. PubMed ID: 30623554
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The effect of the time interval between diagnosis of muscle-invasive bladder cancer and radical cystectomy on staging and survival: A Netherlands Cancer Registry analysis.
    Bruins HM; Aben KK; Arends TJ; van der Heijden AG; Witjes AJ
    Urol Oncol; 2016 Apr; 34(4):166.e1-6. PubMed ID: 26705102
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Role of adjuvant cisplatin-based chemotherapy following radical cystectomy in locally advanced muscle-invasive bladder cancer: Systematic review and meta-analysis of randomized trials.
    Kim DK; Lee JY; Jung JH; Hah YS; Cho KS
    Investig Clin Urol; 2019 Mar; 60(2):64-74. PubMed ID: 30838338
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cystectomy vs. bladder preservation after neoadjuvant chemotherapy in muscle-invasive bladder cancer: A tertiary medical center experience.
    Halabi IE; Husseini ZE; Haibe Y; Charafeddine M; Mukherji D; Temraz S; Bulbul M; Khauli R; Nasr R; Wazzan W; Hajj AE; Geara F; Shamseddine A
    Cancer Treat Res Commun; 2020; 25():100222. PubMed ID: 33080450
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Neoadjuvant chemotherapy plus radical cystectomy versus radical cystectomy alone in clinical T2 bladder cancer without hydronephrosis.
    Soria F; Black PC; Fairey AS; Cookson MS; Yu EY; Kassouf W; Dall'Era MA; Sridhar SS; McGrath JS; Wright JL; Thorpe AC; Morgan TM; Daneshmand S; Holzbeierlein JM; Bivalacqua TJ; North S; Barocas DA; Lotan Y; Grivas P; Stephenson AJ; Shah JB; van Rhijn BW; Spiess PE; Shariat SF; Gontero P
    BJU Int; 2021 Jul; 128(1):79-87. PubMed ID: 33152179
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Neoadjuvant treatment for muscle-invasive bladder cancer: The past, the present, and the future.
    Hermans TJN; Voskuilen CS; van der Heijden MS; Schmitz-Dräger BJ; Kassouf W; Seiler R; Kamat AM; Grivas P; Kiltie AE; Black PC; van Rhijn BWG
    Urol Oncol; 2018 Sep; 36(9):413-422. PubMed ID: 29128420
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Occult lymph node metastases in patients with carcinoma invading bladder muscle: incidence after neoadjuvant chemotherapy and cystectomy vs after cystectomy alone.
    Mertens LS; Meijer RP; Meinhardt W; van der Poel HG; Bex A; Kerst JM; van der Heijden MS; Bergman AM; Horenblas S; van Rhijn BW
    BJU Int; 2014 Jul; 114(1):67-74. PubMed ID: 24053889
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparison of the prognosis of primary and progressive muscle-invasive bladder cancer after radical cystectomy: A systematic review and meta-analysis.
    Chen J; Zhang H; Sun G; Zhang X; Zhao J; Liu J; Shen P; Shi M; Zeng H
    Int J Surg; 2018 Apr; 52():214-220. PubMed ID: 29496649
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Tumor downstaging as an intermediate endpoint to assess the activity of neoadjuvant systemic therapy in patients with muscle-invasive bladder cancer.
    Martini A; Jia R; Ferket BS; Waingankar N; Plimack ER; Crabb SJ; Harshman LC; Yu EY; Powles T; Rosenberg JE; Pal SK; Vaishampayan UN; Necchi A; Wiklund NP; Mehrazin R; Mazumdar M; Sfakianos JP; Galsky MD
    Cancer; 2019 Sep; 125(18):3155-3163. PubMed ID: 31150110
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Blood transfusions during neoadjuvant chemotherapy for muscle-invasive urinary bladder cancer may have a negative impact on overall survival.
    Rosenblatt R; Lorentzi G; Bahar M; Asad D; Forsman R; Johansson M; Shareef M; Alamdari F; Bergh A; Winqvist O; Sherif A
    Scand J Urol; 2020 Feb; 54(1):46-51. PubMed ID: 31960752
    [No Abstract]   [Full Text] [Related]  

  • 37. Neoadjuvant chemotherapy for muscle invasive bladder cancer: a nationwide investigation on survival.
    Russell B; Sherif A; Häggström C; Josephs D; Kumar P; Malmström PU; Van Hemelrijck M
    Scand J Urol; 2019 Aug; 53(4):206-212. PubMed ID: 31174452
    [No Abstract]   [Full Text] [Related]  

  • 38. Delays in radical cystectomy for muscle-invasive bladder cancer.
    Chu AT; Holt SK; Wright JL; Ramos JD; Grivas P; Yu EY; Gore JL
    Cancer; 2019 Jun; 125(12):2011-2017. PubMed ID: 30840335
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Impact of Gender on Chemotherapeutic Response and Oncologic Outcomes in Patients Treated With Radical Cystectomy and Perioperative Chemotherapy for Bladder Cancer: A Systematic Review and Meta-Analysis.
    Kimura S; Iwata T; Abufaraj M; Janisch F; D'Andrea D; Moschini M; Al-Rawashdeh B; Fajkovic H; Seebacher V; Egawa S; Shariat SF
    Clin Genitourin Cancer; 2020 Apr; 18(2):78-87. PubMed ID: 31889669
    [TBL] [Abstract][Full Text] [Related]  

  • 40. History of Non-Muscle-Invasive Bladder Cancer May Have a Worse Prognostic Impact in cT2-4aN0M0 Bladder Cancer Patients Treated With Radical Cystectomy.
    Kayama E; Kikuchi E; Fukumoto K; Shirotake S; Miyazaki Y; Hakozaki K; Kaneko G; Yoshimine S; Tanaka N; Takahiro M; Kanai K; Oyama M; Nakajima Y; Hara S; Monma T; Oya M
    Clin Genitourin Cancer; 2018 Oct; 16(5):e969-e976. PubMed ID: 29778322
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.